Literature DB >> 35411226

Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels.

Qing Kay Li1,2, Tung-Shing Mamie Lih1, Yuefan Wang1, Yingwei Hu1, Naseruddin Höti1, Daniel W Chan1,2,3, Hui Zhang1,2,3.   

Abstract

Prostate cancer (PCa) is a heterogeneous group of tumors, including non-aggressive (NAG) and aggressive (AG) cancer, with variable clinical outcomes. Clinically, in order to assess the aggressiveness of a PCa, a core needle biopsy of a tumor is usually obtained to evaluate the Gleason pattern and score of the tumor. However, it may be difficult to assign on a small biopsy sample using histology. Therefore, additional tool is needed to aid in the assessment. We studied the diagnostic utility of 12 protein markers to identify AG tumors using immunohistochemistry (IHC) and tumor tissue microarray (TMA), including 215 cores of PCa and 111 cores of tumor-matched normal adjacent tissue (NAT). Protein markers were evaluated for their potential utility as single or combined panels for identification of AG. Of 12 proteins, PSMA, phospho-EGFR, AR and P16 were over-expressed in AG. Galectin-3, DPP4 and MAN1B1 revealed stronger staining patterns in NAG. The sensitivity and specificity of individual marker varied widely. Based on AUC values of individual marker, we constructed two- and three-marker panels. In two-marker panels, especially in the panel of DPP4 and PSMA, the AUC value reached 0.83 (ranging from 0.76 to 0.83). In three-marker panels, containing both DPP4 and PSMA with either Galectin-3 or phospho-EGFR, the AUC value reached 0.86 (ranging from 0.83 to 0.86). The specificities at 95% sensitivity of three-marker panels were also significantly improved. In addition to Gleason score, our IHC panels provide a practical tool to assess the aggressiveness of PCa. AJCR
Copyright © 2022.

Entities:  

Keywords:  Prostate cancer; aggressive prostate cancer; immunohistochemistry; protein markers; tumor tissue microarray

Year:  2022        PMID: 35411226      PMCID: PMC8984898     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  46 in total

1.  The Proteogenomic Landscape of Curable Prostate Cancer.

Authors:  Ankit Sinha; Vincent Huang; Julie Livingstone; Jenny Wang; Natalie S Fox; Natalie Kurganovs; Vladimir Ignatchenko; Katharina Fritsch; Nilgun Donmez; Lawrence E Heisler; Yu-Jia Shiah; Cindy Q Yao; Javier A Alfaro; Stas Volik; Anna Lapuk; Michael Fraser; Ken Kron; Alex Murison; Mathieu Lupien; Cenk Sahinalp; Colin C Collins; Bernard Tetu; Mehdi Masoomian; David M Berman; Theodorus van der Kwast; Robert G Bristow; Thomas Kislinger; Paul C Boutros
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

2.  Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.

Authors:  Derek J Gearman; Alessandro Morlacco; John C Cheville; Laureano J Rangel; R Jeffrey Karnes
Journal:  J Urol       Date:  2017-12-07       Impact factor: 7.450

3.  Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.

Authors:  Ahmedin Jemal; MaryBeth B Culp; Jiemin Ma; Farhad Islami; Stacey A Fedewa
Journal:  J Natl Cancer Inst       Date:  2021-01-04       Impact factor: 13.506

4.  Genome-wide germline correlates of the epigenetic landscape of prostate cancer.

Authors:  Kathleen E Houlahan; Yu-Jia Shiah; Alexander Gusev; Jiapei Yuan; Musaddeque Ahmed; Anamay Shetty; Susmita G Ramanand; Cindy Q Yao; Connor Bell; Edward O'Connor; Vincent Huang; Michael Fraser; Lawrence E Heisler; Julie Livingstone; Takafumi N Yamaguchi; Alexandre Rouette; Adrien Foucal; Shadrielle Melijah G Espiritu; Ankit Sinha; Michelle Sam; Lee Timms; Jeremy Johns; Ada Wong; Alex Murison; Michèle Orain; Valérie Picard; Hélène Hovington; Alain Bergeron; Louis Lacombe; Mathieu Lupien; Yves Fradet; Bernard Têtu; John D McPherson; Bogdan Pasaniuc; Thomas Kislinger; Melvin L K Chua; Mark M Pomerantz; Theodorus van der Kwast; Matthew L Freedman; Ram S Mani; Housheng H He; Robert G Bristow; Paul C Boutros
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

5.  The Proteome of Primary Prostate Cancer.

Authors:  Diego Iglesias-Gato; Pernilla Wikström; Stefka Tyanova; Charlotte Lavallee; Elin Thysell; Jessica Carlsson; Christina Hägglöf; Jürgen Cox; Ove Andrén; Pär Stattin; Lars Egevad; Anders Widmark; Anders Bjartell; Colin C Collins; Anders Bergh; Tamar Geiger; Matthias Mann; Amilcar Flores-Morales
Journal:  Eur Urol       Date:  2015-12-02       Impact factor: 20.096

6.  Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.

Authors:  Hafiz Ahmed; Partha P Banerjee; Gerardo R Vasta
Journal:  Biochem Biophys Res Commun       Date:  2007-04-26       Impact factor: 3.575

7.  Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.

Authors:  Thorsten Schlomm; Patrick Kirstein; Liv Iwers; Birte Daniel; Thomas Steuber; Jochen Walz; Felix H K Chun; Alexander Haese; Jens Kollermann; Markus Graefen; Hartwig Huland; Guido Sauter; Ronald Simon; Andreas Erbersdobler
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

8.  Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.

Authors:  Cyril Barinka; Klara Hlouchova; Miroslava Rovenska; Pavel Majer; Miroslawa Dauter; Niyada Hin; Yao-Sen Ko; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2008-01-05       Impact factor: 5.469

9.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

10.  Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors.

Authors:  Qing Kay Li; Jing Chen; Yingwei Hu; Naseruddin Höti; Tung-Shing Mamie Lih; Stefani N Thomas; Li Chen; Sujayita Roy; Alan Meeker; Punit Shah; Lijun Chen; G Steven Bova; Bai Zhang; Hui Zhang
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

View more
  1 in total

1.  Urinary marker panels for aggressive prostate cancer detection.

Authors:  Tung-Shing Mamie Lih; Mingming Dong; Leslie Mangold; Alan Partin; Hui Zhang
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.